Toradol
- Generic Name: ketorolac tromethamine
- Brand Name: Toradol
Toradol (Ketorolac Tromethamine) side effects drug center
- Related Drugs
- Drug Comparison
- Toradol User Reviews
Toradol Side Effects Center
What Is Toradol?
Toradol (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat moderately severe pain and inflammation, usually after surgery. Toradol works by blocking the production of prostaglandins, compounds that cause pain, fever, and inflammation. The brand name Toradol is no longer available in the U.S. Generic versions may be available.
What Are Side Effects of Toradol?
Common side effects of Toradol include:
- headache,
- heartburn,
- upset stomach,
- nausea,
- vomiting,
- diarrhea,
- stomach pain,
- bloating,
- gas,
- constipation,
- dizziness,
- drowsiness,
- sweating,
- and ringing in the ears.
Dosage for Toradol
Toradol is available as a 10 mg tablet and a solution (30 mg per ml) for intravenous (IV) or intramuscular (IM) administration. Toradol solution is administered as a single 15- to 60-mg dose once every 6 hours not to exceed 60 or 120 mg a day. The recommended oral dose is one to two Toradol tablets initially followed by one tablet every 4-6 hours, not to exceed 40 mg daily. Toradol should not be used for more than 5 days.
What Drugs, Substances, or Supplements Interact with Toradol?
Drug interactions may occur with lithium, ACE inhibitors, warfarin, and medications used to treat high uric acid levels. Warnings may apply to individuals who have ulcers, cardiovascular disease, kidney disease, and bleeding disorders. People who are taking aspirin or NSAIDs should not take Toradol because of the cumulative risk of inducing serious NSAID-related side effects.
Toradol During Pregnancy and Breastfeeding
Toradol is generally avoided during pregnancy. Pregnant women may take Toradol only if it is clearly needed and the potential benefit justifies the potential risk to the fetus. Nursing mothers should not take Toradol, because it is excreted in breast milk. Toradol solution may be used as a single dose in children in certain instances, but safety and effectiveness in the pediatric population is not established.
Additional Information
Our Toradol Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Toradol Consumer Information
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).
Get emergency medical help if you have signs of a heart attack or stroke: chest pain spreading to your jaw or shoulder, sudden numbness or weakness on one side of the body, slurred speech, feeling short of breath.
Stop using ketorolac and call your doctor at once if you have:
- shortness of breath (even with mild exertion);
- swelling or rapid weight gain;
- a skin rash, no matter how mild;
- signs of stomach bleeding--bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
- liver problems--loss of appetite, stomach pain (upper right side), tiredness, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
- kidney problems--little or no urination, swelling in your feet or ankles, feeling tired or short of breath; o
- low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet.
Common side effects may include:
- nausea, stomach pain, indigestion, diarrhea;
- dizziness, drowsiness;
- headache; or
- swelling.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Toradol (Ketorolac Tromethamine)
Toradol Professional Information
SIDE EFFECTS
Adverse reaction rates increase with higher doses of TORADOL (ketorolac tromethamine) . Practitioners should be alert for the severe complications of treatment with TORADOL (ketorolac tromethamine) , such as GI ulceration, bleeding and perforation, postoperative bleeding, acute renal failure, anaphylactic and anaphylactoid reactions and liver failure (see BOXED WARNING, WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION). These NSAID-related complications can be serious in certain patients for whom TORADOL (ketorolac tromethamine) is indicated, especially when the drug is used inappropriately.
In patients taking TORADOL (ketorolac tromethamine) or other NSAIDs in clinical trials, the most frequently reported adverse experiences in approximately 1% to 10% of patients are:
Gastrointestinal (GI) experiences including: | ||
abdominal pain* | constipation/diarrhea | dyspepsia* |
flatulence | GI fullness | GI ulcers (gastric/duodenal) |
gross bleeding/perforation | Heartburn | nausea* |
stomatitis | Vomiting | |
Other experiences: | ||
abnormal renal function | Anemia | dizziness |
drowsiness | Edema | elevated liver enzymes |
headaches* | Hypertension | increased bleeding time |
injection site pain | Pruritus | purpura |
rashes | Tinnitus | sweating |
*Incidence greater than 10% |
Additional adverse experiences reported occasionally ( < 1% in patients taking TORADOL (ketorolac tromethamine) or other NSAIDs in clinical trials) include:
Body as a Whole: fever, infections, sepsis
Cardiovascular: congestive heart failure, palpitation, pallor, tachycardia, syncope
Dermatologic: alopecia, photosensitivity, urticaria
Gastrointestinal: anorexia, dry mouth, eructation, esophagitis, excessive thirst, gastritis, glossitis, hematemesis, hepatitis, increased appetite, jaundice, melena, rectal bleeding
Hemic and Lymphatic: ecchymosis, eosinophilia, epistaxis, leukopenia, thrombocytopenia
Metabolic and Nutritional: weight change
Nervous System: abnormal dreams, abnormal thinking, anxiety, asthenia, confusion, depression, euphoria, extrapyramidal symptoms, hallucinations, hyperkinesis, inability to concentrate, insomnia, nervousness, paresthesia, somnolence, stupor, tremors, vertigo, malaise
Reproductive, female: infertility
Respiratory: asthma, cough, dyspnea, pulmonary edema, rhinitis
Special Senses: abnormal taste, abnormal vision, blurred vision, hearing loss
Urogenital: cystitis, dysuria, hematuria, increased urinary frequency, interstitial nephritis, oliguria/polyuria, proteinuria, renal failure, urinary retention
Other rarely observed reactions (reported from postmarketing experience in patients taking TORADOL (ketorolac tromethamine) or other NSAIDs) are:
Body as a Whole: angioedema, death, hypersensitivity reactions such as anaphylaxis, anaphylactoid reaction, laryngeal edema, tongue edema (see WARNINGS), myalgia
Cardiovascular: arrhythmia, bradycardia, chest pain, flushing, hypotension, myocardial infarction, vasculitis
Dermatologic: exfoliative dermatitis, erythema multiforme, Lyell's syndrome, bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
Gastrointestinal: acute pancreatitis, liver failure, ulcerative stomatitis, exacerbation of inflammatory bowel disease (ulcerative colitis, Crohn's disease)
Hemic and Lymphatic: agranulocytosis, aplastic anemia, hemolytic anemia, lymphadenopathy, pancytopenia, postoperative wound hemorrhage (rarely requiring blood transfusion - see BOXED WARNING, WARNINGS, and PRECAUTIONS)
Metabolic and Nutritional: hyperglycemia, hyperkalemia, hyponatremia
Nervous System: aseptic meningitis, convulsions, coma, psychosis
Respiratory: bronchospasm, respiratory depression, pneumonia
Special Senses: conjunctivitis
Urogenital: flank pain with or without hematuria and/or azotemia, hemolytic uremic syndrome
Postmarketing Surveillance Study
A large postmarketing observational, nonrandomized study, involving approximately 10,000 patients receiving ketorolac tromethamineIV/IM, demonstrated that the risk of clinically serious gastrointestinal (GI) bleeding was dose-dependent (see Tables 3A and 3B). This was particularly true in elderly patients who received an average daily dose greater than 60 mg/day of ketorolac tromethamineIV/IM (see Table 3A).
Table 3 Incidence of Clinically Serious GI Bleeding as Related to Age, Total Daily Dose, and History of GI Perforation, Ulcer, Bleeding (PUB) After up to 5 Days of Treatment With Ketorolac TromethamineIV/IMA.
A. Adult Patients Without History of PUB | ||||
Age of Patients | Total Daily Dose of Ketorolac TromethamineIV/IM | |||
≤ 60 mg | > 60 to 90 mg | > 90 to 120 mg | > 120 mg | |
< 65 years of age | 0.4% | 0.4% | 0.9% | 4.6% |
≥ 65 years of age | 1.2% | 2.8% | 2.2% | 7.7% |
B. Adult Patients With History of PUB | ||||
Age of Patients | Total Daily Dose of Ketorolac TromethamineIV/IM | |||
≤ 60 mg | > 60 to 90 mg | > 90 to 120 mg | > 120 mg | |
< 65 years of age | 2.1% | 4.6% | 7.8% | 15.4% |
≥ 65 years of age | 4.7% | 3.7% | 2.8% | 25.0% |
Read the entire FDA prescribing information for Toradol (Ketorolac Tromethamine)
&Copy; Toradol Patient Information is supplied by Cerner Multum, Inc. and Toradol Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.